Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy

PLoS Medicine 2026 Open access

Read full text
Authors: Giulia Notini, Giampaolo Bianchini, José Manuel Pérez-García, Javier Cortés
DOI: 10.1371/journal.pmed.1004930
Cited by: 3
References: 11

Abstract

Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Breast Cancer Treatment Studies

Publication details

Journal / source
PLoS Medicine
Publisher
Public Library of Science (PLoS)
Volume
23
Issue
1
Pages
e1004930–e1004930
Publication date
30 January 2026
Language
EN